Member Info for mathsprof

Ah, sorry. I knew I wasn't answering your question. The percentages refer to the change in their short positions. Add (subtract) the percentage to previously reported %, to get new position.

As for whether they are making money it all depends on the trade times in the day. So even the charts wouldn't help!

From what I can see, the shorts in the UK are around 1.7%, but in the US a much higher 6%.
£300m in UK plus $1.57b in the US.
You'd need to compare the shrt chart/table with the SP chat/table to know who's making or losing money.
UK short positions show good rise this week, yet SP increasing too. ...???

I think the slide over the last 2 weeks was partly due to the debt refinancing - and the uncertainty of it. So after the successful completion anncouncement, the price is recovering. Drop overdone, some reality resumed. But I don't expect to go back to the height we fell from for quite some time. Short term target - £15.

The current programme is limited to a maximum of about 10% UK stock. So no threat of delisting. It will take approx 20 weeks to achieve this amount of buy-backs at the current rate. So expect a lot more RNSs. The effect has already been seen on the discount of UK to US stock. Without the buy-back we would probably be almost £1 lower than we are - and/or the US price would be $1.50 higher.
The situation is confused because both SPs have fallen for reasons independent to the buy-back.

UK news isn't going to move the SP much. UK is only one market out of many.
What actually matters is debt, cash burn, profit projections etc...
The picture here is not very encouraging yet.
£15 seems a good buy price, but I wouldn't be surprised to see SP around £15 again in Q4.

The UK shares will be/are being purchased on the open market from the MMs. Individuals will continue to hold all their shares and cannot sell direct to CCL.
The repurchsed shares will not be delisted, but held by CCL (and thus theoretically could be resold in the market should they wish).

The shares only differ in that the UK shares don't have the same voting rights as the US ones. That's the main reason for the discount.

I won't be too worried about TB's share sales until he cashes in and sells his 1.2m 2030 options.

CCL intend to raise capital by selling new US shares, and use the proceeds to buy back UK shares., thus making a profit in the process. The effect of this RNS news is we can expect to see a good reduction in the UK/US price discount. Historically it has been as low (or lower?) than 10%. Yesterday it was around 18%. At today's UK close it had dropped to under 15%.
So the news is good for UK shares, and bad for US shares. Hence the large drop of 7% in the US, and only a small drop here. Probably an over-reaction.

Haha. With Val there was always the chance of buying in below 0.2p. But that was a few years ago. Maybe we'll go under 18p again before the end of June.

Perhaps some brokers allow small trades. A 4 trade went through today.

So how do the 1 share "signals" work!! MMs perogative, I suppose!

year1970
A belated reply. You're right that you actually couldn't sell 6 shares - if you could it would be giving money away.
I first bought VAL in 2011 and the SP was around 0.6p. My original holding of 300000 has been consolidated twice to 19 shares - and the fraction of 0.2 lost. In the same way 100000 (?) bought at 0.745p (say) would now be only 6 shares.

Your 6 shares are now worth £1.20 and as pointed out could only be sold at a loss. So, I suggest, mentally write off your £743.80, keep the 6 shares and buy some more.

For the record, you previously held at least 93750 shares, which have been consolidated twice.

What a disgrace. Spread still shown as 7.20 - 7.35p. 7.52p sells going through at a rate of knots after a lot of 7.60p buys.
Clever old scuMMs.

Here's the details:

Seriously ill COVID patients could be treated with first UK antiviral drug proven to save lives in hospital

People who get seriously ill from coronavirus in the UK could soon be offered the first antiviral drug shown to save lives of patients admitted to hospital, researchers have said.

Regeneron has been proven to reduce the risk of death in severely ill COVID-19 patients by helping those who have not been able to produce an antibody response to the virus naturally.

It has been shown to reduce their chances of dying, being put on a ventilator and shorten their time in hospital, the scientists said.

Between 18 September 2020 and 22 May 2021, 9,785 UK patients admitted to hospital with the disease were randomly allocated to receive usual care plus the antibody combination treatment, or usual care alone.

Researchers on the Recovery Trial found that among patients who received usual care alone, 28-day mortality was twice as high in those without an antibody response (30%) compared with those who were seropositive (15%) at the start of the study.

According to the study, for patients who had no antibody response the treatment reduced the chance of them dying within 28 days by a fifth, compared with usual care alone.

For every 100 such patients treated with the antibody combination, there would be six fewer deaths.

Strange.
My time stamp on post is 2 minutes fast???It is now 1709

There it is 429500 @1707.

UT at 1635 of 7p is close. Pedict another 7p trade very soon - probably large.

This may make one or two rethink booking a cruise.

https://breaking911.com/2-passengers-on-first-fully-vaccinated-north-american-cruise-test-positive-for-covid/